FDA approval: Ryoncil (from Catapult’s regulatory round-up for December 2024)
FDA has approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Steroid-refractory acute graft-versus-host...